If you understood the company you would realise this "golden goose" is actually just the proof-of-concept disease that shows the amazing safety of the clinuvel drug and at the same time gathers data and gives authorities confidence in the company and what other diseases they can potentially treat.
Scenesse actually treats EPP and vitiligo by providing an artificial suntan - exactly the same as Epitan.
This is where you are going to see the real BIG FARM OF GOLDEN GEESE when Clinuvel get approval for their existing drug to treat Vitiligo, XP, VP, OTRs (organ transplant recipients), skin cancer sufferers, Stroke victims (85% of 15 Million currently untreated) and with their OTC products for people who want solar protection and DNA repair - so pretty much everyone!
CUV have treated one stroke patient. It will take another five years for the trials and approval process. The realistic chances of success are only 5-10%.
Every new purpose will need separate clinical trials and approval.
Don't believe the hype. Alpha-MSH drugs have been ignored by Big Pharma for 40 years because they are not particularly useful.
Clinuvel has now achieved FDA, EMA, TGA and Israel market approval for their drug and very, very few Australian biotechs can boast anything like this achievement.
You totally fail to understand that it is far easier to get Orphan Drug status. They have lower barriers for safety and efficacy and a much more streamlined approval process.
Furthermore CUV is also very undervalued compared to comparison stocks like MSB, TLX and PNV who have similar or higher valuations despite not being profitable and just burning cash and they do not have the approvals that CUV has.
Total nonsense. Each of these companies operate in totally different sectors. They have absolutely nothing in common and can't be compared.
CUV Price at posting:
$27.48 Sentiment: None Disclosure: Not Held
(20min delay)